Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells.
about
RNA design rules from a massive open laboratoryProgress toward in vivo use of siRNAs-IIFolate Receptor Targeted Delivery of siRNA and Paclitaxel to Ovarian Cancer Cells via Folate Conjugated Triblock Copolymer to Overcome TLR4 Driven Chemotherapy Resistance.Ultrasound-triggered disruption and self-healing of reversibly cross-linked hydrogels for drug delivery and enhanced chemotherapyDevelopment of nanoscale approaches for ovarian cancer therapeutics and diagnosticsFunctional Aspects of PARP1 in DNA Repair and Transcription.Facet-specific assembly of proteins on SrTiO₃ polyhedral nanocrystals.Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regressionSilencing HoxA1 by intraductal injection of siRNA lipidoid nanoparticles prevents mammary tumor progression in mice.The combination of ANT2 shRNA and hNIS radioiodine gene therapy increases CTL cytotoxic activity through the phenotypic modulation of cancer cells: combination treatment with ANT2 shRNA and I-131Folate receptor-targeted multimodality imaging of ovarian cancer in a novel syngeneic mouse modelDrug therapy for hereditary cancersSynergistic silencing: combinations of lipid-like materials for efficacious siRNA deliveryGalactosylated Lipidoid Nanoparticles for Delivery of Small Interfering RNA to Inhibit Hepatitis C Viral Replication In Vivo.A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancerTargeted delivery of siRNA-generating DNA nanocassettes using multifunctional nanoparticles.Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumour-associated macrophages and cancer cells.Indium-Labeling of siRNA for Small Animal SPECT Imaging.CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving TargetsThe Sound of Silence: RNAi in Poly (ADP-Ribose) ResearchIn vivo imaging of the systemic delivery of small interfering RNA.Nanocarrier systems for delivery of siRNA to ovarian cancer tissues.Current views on inducing synthetic lethal RNAi responses in the treatment of cancer.Hydrogel doped with nanoparticles for local sustained release of siRNA in breast cancer.Biodistribution studies of nanoparticles using fluorescence imaging: a qualitative or quantitative method?Evaluation of liposomal behavior in the gastrointestinal tract after oral administration using real-time in vivo imaging.Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C.Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer.Solving the RNA design problem with reinforcement learning.Advantages and Limitations of Current Techniques for Analyzing the Biodistribution of NanoparticlesMicroRNA (miR) 125b regulates cell growth and invasion in pediatric low grade gliomaInflammation is a key contributor to ovarian cancer cell seeding
P2860
Q24206632-F850E306-EB7D-4229-B47B-D8E324E04CC9Q28255877-79C69EF6-5756-44E7-B98E-23FB0E8D160BQ30365844-AEAE7CE4-A3A3-4401-AAA4-2CCE00A4F742Q30421156-731EA050-4836-47C2-BC68-5E186ADE899DQ30421664-E9D93F1F-56DC-4112-8CF9-1691ED1A1364Q33649584-E90B41DC-63FA-48F1-961B-C6FD99736000Q33671950-F1C105A1-9907-4A11-9555-0182C4EC702DQ34136997-2DECCCEB-AA43-403B-B443-4650150CA71CQ34395225-4B834BEC-C9F4-42F4-908C-07E23508A65BQ34632674-073484AF-2AB7-4A6B-A810-A1EC2A4C9A0DQ35057527-344162DB-2DE0-4135-936B-D84037E55C1EQ35208929-9571316D-72A2-476C-91F6-323DE20B8911Q35238275-DB9CD5ED-8EDD-46A5-9532-A7D95409305FQ36172753-059E7D30-8AE7-47D3-9CF8-5A0145AAD37CQ36186347-9A15F0CD-AD2D-4A2D-96C3-76F068E14B52Q36906374-074551BD-8381-4F09-BAC3-AC393E1C801AQ37021458-7E6B6A73-5B09-4EC3-AE71-CCB7D12B809CQ37076674-68CE9918-F4A8-47CE-872D-627FD279BF95Q37173597-05526B85-ABBC-4CF6-8053-9AE7A1216B5CQ37307055-592BE091-0753-4105-9C70-68C203CF5694Q37508170-EC810979-214C-4398-B3C3-765BBB439B03Q37974175-5DE890D7-3ED1-448E-8F9F-A368961FFB49Q38015511-20C034E5-868C-479C-94FC-8F49496026E7Q38656763-07EAB7D2-A9EE-4E30-8F4B-C720AF5D4EECQ38967041-C1156F9D-9C3F-45EF-B967-D96B9F40B885Q43238303-C9A2480E-4F07-45FD-AB32-6FC84EBD9377Q47322840-B80A8D52-FE75-4E2B-B997-801ED4413AC4Q47581752-AAA1A945-9246-43B1-98D8-C27AA06C2775Q49852384-9B9509C9-8C7A-4951-AB47-9BF1BEA98DCAQ55209147-1D9FA201-86EB-4026-A686-E303D0E96ED0Q57181636-7352B193-E099-4194-9658-498FF7642223Q58730599-FA87F6C6-1317-4489-AEB1-31CBADB1F4E6Q58771020-FB36A038-3A82-48BB-A503-B371A5465A8A
P2860
Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Nanoparticle-mediated delivery ...... eficient ovarian cancer cells.
@ast
Nanoparticle-mediated delivery ...... eficient ovarian cancer cells.
@en
Nanoparticle-mediated delivery ...... eficient ovarian cancer cells.
@nl
type
label
Nanoparticle-mediated delivery ...... eficient ovarian cancer cells.
@ast
Nanoparticle-mediated delivery ...... eficient ovarian cancer cells.
@en
Nanoparticle-mediated delivery ...... eficient ovarian cancer cells.
@nl
prefLabel
Nanoparticle-mediated delivery ...... eficient ovarian cancer cells.
@ast
Nanoparticle-mediated delivery ...... eficient ovarian cancer cells.
@en
Nanoparticle-mediated delivery ...... eficient ovarian cancer cells.
@nl
P2093
P2860
P356
P1476
Nanoparticle-mediated delivery ...... eficient ovarian cancer cells.
@en
P2093
Deyin Xing
Michael S Goldberg
Phillip A Sharp
Sandra Orsulic
Sangeeta N Bhatia
P2860
P304
P356
10.1073/PNAS.1016538108
P407
P577
2010-12-27T00:00:00Z